

Edgar Filing: LYNX THERAPEUTICS INC - Form SC 13G/A

LYNX THERAPEUTICS INC  
Form SC 13G/A  
February 04, 2005

SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

SCHEDULE 13G  
(Rule 13d-102)

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES  
13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b)

(Amendment No. 1)\*

Lynx Therapeutics, Inc.

-----  
(Name of Issuer)

Common Stock, \$0.01 par value per share

-----  
(Title of Class of Securities)

551812-30-8

-----  
(CUSIP Number)

December 31, 2004

-----  
(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule  
is filed:

- Rule 13d-1(b)
- Rule 13d-1(c)
- Rule 13d-1(d)

\*The remainder of this cover page shall be filled out for a reporting person's  
initial filing on this form with respect to the subject class of securities, and  
for any subsequent amendment containing information which would alter the  
disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed  
to be "filed" for the purpose of Section 18 of the Securities Exchange Act of  
1934 ("Act") or otherwise subject to the liabilities of that section of the Act  
but shall be subject to all other provisions of the Act (however, see the  
Notes).

SCHEDULE 13G

CUSIP NO. 551812-30-8

Page 2 of 7

-----  
1 NAMES OF REPORTING PERSONS  
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (Entities Only)

Cranshire Capital, L.P.

-----  
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a)   
(b)

-----  
3 SEC USE ONLY

Edgar Filing: LYNX THERAPEUTICS INC - Form SC 13G/A

4 CITIZENSHIP OR PLACE OF ORGANIZATION

Illinois

NUMBER OF 5 SOLE VOTING POWER

SHARES N/A

BENEFICIALLY 6 SHARED VOTING POWER

OWNED BY N/A

EACH 7 SOLE DISPOSITIVE POWER

REPORTING N/A

PERSON 8 SHARED DISPOSITIVE POWER

WITH N/A

9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

N/A

10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

[ ]

11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

Less than 5%

12 TYPE OF REPORTING PERSON

PN

SCHEDULE 13G

CUSIP NO. 551812-30-8

Page 3 of 7

1 NAMES OF REPORTING PERSONS

I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (Entities Only)

Downsview Capital, Inc.

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) [ ]

(b) [ ]

3 SEC USE ONLY

4 CITIZENSHIP OR PLACE OF ORGANIZATION

Illinois

NUMBER OF 5 SOLE VOTING POWER

SHARES N/A

BENEFICIALLY 6 SHARED VOTING POWER

Edgar Filing: LYNX THERAPEUTICS INC - Form SC 13G/A

OWNED BY N/A  
-----  
EACH 7 SOLE DISPOSITIVE POWER  
REPORTING N/A  
-----  
PERSON 8 SHARED DISPOSITIVE POWER  
WITH N/A  
-----

9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
N/A  
-----

10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES  
[ ]  
-----

11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
Less than 5%  
-----

12 TYPE OF REPORTING PERSON  
CO  
-----

SCHEDULE 13G

CUSIP NO. 551812-30-8

Page 4 of 7

-----  
1 NAMES OF REPORTING PERSONS  
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (Entities Only)  
Mitchell P. Kopin  
-----

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) [ ]  
(b) [ ]  
-----

3 SEC USE ONLY  
-----

4 CITIZENSHIP OR PLACE OF ORGANIZATION  
U.S.A.  
-----

NUMBER OF 5 SOLE VOTING POWER  
SHARES N/A  
-----

BENEFICIALLY 6 SHARED VOTING POWER  
OWNED BY N/A  
-----

EACH 7 SOLE DISPOSITIVE POWER  
REPORTING N/A  
-----

PERSON 8 SHARED DISPOSITIVE POWER  
WITH N/A  
-----

Edgar Filing: LYNX THERAPEUTICS INC - Form SC 13G/A

9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

N/A

10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

[ ]

11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

Less than 5%

12 TYPE OF REPORTING PERSON

IN

SCHEDULE 13G

CUSIP NO. 551812-30-8

Page 5 of 7

Item 1(a). Name of Issuer:

Lynx Therapeutics, Inc., a Delaware corporation (the "Issuer")

Item 1(b). Address of Issuer's Principal Executive Offices:

25861 Industrial Blvd.  
Hayward, CA 94545

Items 2(a),  
(b) and (c). Name of Persons Filing, Address of Principal Business Office and  
Citizenship:

This Amendment No. 1 to Schedule 13G is being filed on behalf of  
(i) Cranshire Capital, L.P., an Illinois limited partnership  
("Cranshire"), (ii) Downsvew Capital, Inc., an Illinois  
corporation ("Downsvew") and (iii) Mitchell P. Kopin, an  
individual who is a citizen of the U.S.A. ("Kopin," together with  
Cranshire and Downsvew, the "Reporting Persons").

The Reporting Persons have entered into a Joint Filing Agreement,  
a copy of which is filed with this Amendment No. 1 to Schedule  
13G as Exhibit 1, pursuant to which the Reporting Persons have  
agreed to file this Amendment No. 1 to Schedule 13G jointly in  
accordance with the provisions of Rule 13d-1(k) of the Securities  
Exchange Act of 1934, as amended.

The principal business office of each of the Reporting Persons is  
666 Dundee Road, Suite 1901, Northbrook, Illinois, 60062.

Item 2(d). Title of Class of Securities:

Common Stock, par value \$0.01 per share, of the Issuer (the  
"Common Stock")

Item 2(e). CUSIP Number:

551812-30-8

Item 3. Not applicable.

Edgar Filing: LYNX THERAPEUTICS INC - Form SC 13G/A

Item 4. Ownership.

(a) Amount beneficially owned:

N/A

(b) Percent of class:

Less than 5%

SCHEDULE 13G

CUSIP NO. 551812-30-8

Page 6 of 7

(c) Number of shares to which such person has:

(i) Sole power to vote or direct the vote: N/A

(ii) Shared power to vote or direct the vote: N/A

(iii) Sole power to dispose or to direct the disposition of:  
N/A

(iv) Shared power to dispose of or direct the disposition  
of: N/A

Item 5. Ownership of Five Percent or Less of a Class.

If this statement is being filed to report the fact that as of the date hereof the reporting persons have ceased to be the beneficial owner of more than five percent of the class of securities, check the following [X]

Item 6. Ownership of More than Five Percent on Behalf of Another Person.

N/A

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported By the Parent Holding Company.

N/A

Item 8. Identification and Classification of Members of the Group.

N/A

Item 9. Notice of Dissolution of a Group.

N/A

Item 10. Certification.

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

SCHEDULE 13G

CUSIP NO. 551812-30-8

Page 7 of 7

Edgar Filing: LYNX THERAPEUTICS INC - Form SC 13G/A

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: February 4, 2005

CRANSHIRE CAPITAL, L.P.

By: Downsview Capital, Inc.,  
its general partner

By:/s/ Mitchell P. Kopin

-----  
Mitchell P. Kopin, President

DOWNSVIEW CAPITAL, INC.

By:/s/ Mitchell P. Kopin

-----  
Mitchell P. Kopin, President

/s/ Mitchell P. Kopin

-----  
Mitchell P. Kopin

SCHEDULE 13G

CUSIP NO. 551812-30-8

Exhibit 1

JOINT FILING AGREEMENT

In accordance with Rule 13d 1(k) under the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to certain shares of Common Stock, par value \$0.01 per share, of Lynx Therapeutics, Inc., and further agree that this Joint Filing Agreement shall be included as an exhibit to such joint filings.

The undersigned further agree that each party hereto is responsible for the timely filing of such Schedule 13G and any amendments thereto, and for the completeness and accuracy of the information concerning such party contained therein; provided, however, that no party is responsible for the completeness or accuracy of the information concerning any other party making the filing, unless such party knows or has reason to believe that such information is inaccurate.

IN WITNESS WHEREOF, the parties have executed this Joint Filing Agreement on February 4, 2005.

CRANSHIRE CAPITAL, L.P.

By: Downsview Capital, Inc.,

Edgar Filing: LYNX THERAPEUTICS INC - Form SC 13G/A

its general partner

By:/s/ Mitchell P. Kopin

-----  
Mitchell P. Kopin, President

DOWNSVIEW CAPITAL, INC.

By:/s/ Mitchell P. Kopin

-----  
Mitchell P. Kopin, President

/s/ Mitchell P. Kopin

-----  
Mitchell P. Kopin